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Pachychoroid neovasculopathy 
and age-related macular 
degeneration
Masahiro Miyake1,2, Sotaro Ooto1, Kenji Yamashiro1, Ayako Takahashi1, 
Munemitsu Yoshikawa1, Yumiko Akagi-Kurashige1, Naoko Ueda-Arakawa1, Akio Oishi1, 
Hideo Nakanishi1, Hiroshi Tamura1, Akitaka Tsujikawa1,3 & Nagahisa Yoshimura1
Pachychoroid neovasculopathy is a recently proposed clinical entity of choroidal neovascularization 
(CNV). As it often masquerades as neovascular age-related macular degeneration (AMD), it is 
currently controversial whether pachychoroid neovasculopathy should be distinguished from 
neovascular AMD. This is because its characteristics have yet to be well described. To estimate the 
relative prevalence of pachychoroid neovasculopathy in comparison with neovascular AMD and to 
investigate the phenotypic/genetic differences of the two diseases, we evaluated 200 consecutive 
Japanese patients who agreed to participate in the genetic study and diagnosed with pachychoroid 
neovasculopathy or neovascular AMD. Pachychoroid neovasculopathy was observed in 39 individuals 
(19.5%), which corresponds to one fourth of neovascular AMD. Patients with pachychoroid 
neovasculopathy were significantly younger (p = 5.1 × 10−5) and showed a greater subfoveal 
choroidal thickness (p = 3.4 × 10−14). Their genetic susceptibility to AMD was significantly lower than 
that of neovascular AMD; ARMS2 rs10490924 (p = 0.029), CFH rs800292 (p = 0.013) and genetic risk 
score calculated from 11 AMD susceptibility genes (p = 3.8 × 10−3). Current results implicate that the 
etiologies of the two conditions must be different. Thus, it will be necessary to distinguish these two 
conditions in future studies.
Age-related macular degeneration (AMD) is a major cause of progressive visual impairment in developed 
countries1–3. After the discovery of the major AMD susceptibility genes ARMS2 and CFH4–7, AMD has 
been thought to be a genetically homogenous disease. However, it is well known that the clinical char-
acteristics of neovascular AMD are somewhat different between Asians and Caucasians. For example, 
the prevalence of large soft drusen in the unaffected eye is significantly lower in Asians, compared with 
Caucasians8. Likewise, polypoidal choroidal neovascularization (PCV) is a common subtype of neovas-
cular AMD in Asians, while this is not the case for Caucasians.8It seems unlikely that such a substantial 
heterogeneity of a single disease can be solely attributed to different ethnic characteristics.
It has been reported that patients with PCV often have a history of central serous chorioretinop-
athy (CSC). These two conditions share characteristics such as a thick choroid and a good response 
to photodynamic therapy. For these reasons, the association between PCV and CSC has been widely 
investigated9–11. Several groups have reported that eyes with neovascular AMD with choroidal vascular 
hyperpermeability, a characteristic of CSC, have a thicker choroid12,13. Furthermore, CNVs with choroi-
dal hyperpermeability have a different genotype distribution from those without14. However, CNV in 
cases where there is a history of diagnosed CSC, or characteristics of CSC, is often misdiagnosed as a 
peculiar type of neovascular AMD. This applies even in cases where there are no drusen, since it had not 
been well established that CSC itself might lead to CNV.
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Recently, several researchers have proposed a restructuring of the neovascular AMD, PCV, and CSC 
spectrum. In 2012, Fung et al. reported that type 1 CNV can develop in long standing CSC and can 
masquerade as neovascular AMD15. In 2013, Warrow et al. described a new clinical entity character-
ized by a range of retinal pigment epithelium (RPE) abnormalities overlying areas of choroidal thick-
ening. The researchers termed the condition “pachychoroid pigment epitheliopathy (PPE)”16. In 2014, 
Pang and Freund reported a small series of cases involving patients with CNV occurring over areas of 
increased choroidal thickness and dilated choroidal vessels. They termed this “pachychoroid neovascu-
lopathy”17. These eyes did not have drusen or degenerative changes to suggest AMD or other degener-
ative diseases. Pang and Freund speculated that the cause of pachychoroid neovasculopathy might be a 
pachychoroid-driven process such as choroidal congestion and choroidal hyperpermeability manifested 
by choroidal thickening and dilated choroidal vessels.
Pachychoroid neovasculopathy is characterized by thick choroid, RPE abnormalities, and/or choroi-
dal vascular hyperpermeability. It has been suggested that it resides within a spectrum of diseases that 
includes PPE, CSC, and PCV. Most importantly, pachychoroid neovasculopathy often masquerades as 
neovascular AMD, so that the original report caution against the misdiagnosis of pachychoroid neo-
vasculopathy as neovascular AMD15,17. We hypothesized that many patients with pachychoroid neovas-
culopathy may have been misdiagnosed in this way. This is particularly plausible in the case of Asian 
patients, in whom CSC is common. The purpose of this study was to estimate the relative prevalence 
of pachychoroid neovasculopathy compared with neovascular AMD using multiple imaging methods. 
Moreover, we investigated the differences between the two conditions with respect to clinical character-
istics and genotype distribution.
Results
A total of 200 patients met the criteria for the current study. The demographics of the study population 
are summarized in Table  1. Mean age was 74.3 yr (SD = 8.8 yr). Characteristics were not significantly 
different between right and left eyes. Pseudodrusen and calcified drusen were observed in 9.0% and 
1.0–1.5% of the study population, respectively. Approximately 30% of the eyes had RPE abnormality 
independent of the CNV lesion, and 15% of the eyes had choroidal vascular hyperpermeability. Mean 
subfoveal choroidal thickness was 227 μ m (SD = 101 μ m) in right eyes and 229 μ m (SD = 109 μ m) in left 
eyes.
Thirty-nine (19.5%) of the participants were diagnosed with pachychoroid neovasculopathy, and 161 
(80.5%) patients were diagnosed with neovascular AMD. The characteristics of both groups are shown 
in Table 2. Patients with pachychoroid neovasculopathy were significantly younger than those with neo-
vascular AMD (68.7 yr, vs. 75.6 yr, respectively; p = 5.1 × 10−5). They also had greater subfoveal choroi-
dal thickness (p = 3.4 × 10−14). Although RPE abnormality and choroidal vascular hyperpermeability 
were more common in patients with pachychoroid neovasculopathy (p = 7.9 × 10−12 and 4.5 × 10−7, 
respectively), they were also found in 30.4% and 13.6%, respectively, of patients with neovascular AMD. 
Laterality
Right eyes Left eyes
Number of patients 200
Age (years) 74.3 ± 8.8‡
Sex (male:female) 143:57
Refraction (diopter) 0.24 ± 2.30‡ 0.23 ± 2.19‡
Drusen
   No drusen or only non-extensive hard drusen 41 (20.5%) 42 (21.0%)
   Large soft drusen 52 (26.0%) 53 (26.5%)
   Extensive soft drusen* 33 (16.5%) 27 (13.5%)
   Pseudodrusen 18 (9.0%) 18 (9.0%)
   Calcified drusen 3 (1.5%) 2 (1.0%)
RPE abnormality apart from the CNV legion 61 (30.5%) 58 (29.0%)
Choroidal vascular dilatation (0:1:2:3)† 123:56:20:1 134:48:14:4
Choroidal vascular hyperpermeability 33 (16.5%) 28 (14.0%)
Subfoveal choroidal thickness (μ m) 227± 101‡ 229 ± 109‡
Table 1.  Characteristics of the study population. *More than 6 drusen (> 63 μ m each) in ETDRS grid. 
†Number of quadrants. ‡mean ± standard deviation are shown. AREDS: Age-related Eye Disease Study, RPE: 
retianl pigment epithelium. CNV: choroidal neovascularization. ETDRS: early treatment diabetic retinopathy 
study.
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Although choroidal vascular dilatation and polypoidal lesion tended to exist more in pachychoroid neo-
vasculopathy, the difference were not statistically significant (p = 0.093 and 0.11, respectively).
Table 3 and Fig. 1 show the genetic profiles of pachychoroid neovasculopathy and neovascular AMD. 
The genotype distribution of both ARMS2 A69S and CFH I62V differed significantly between the two 
conditions (Table 3). The frequency of the T allele in ARMS2 A69S was 51.3% and 64.8%, respectively, 
in patients with pachychoroid neovasculopathy and neovascular AMD (p = 0.029). The frequency of the 
A allele in CFH I62V was 41.0% and 25.5%, respectively, in patients with pachychoroid neovasculopathy 
and neovascular AMD (p = 0.013). These results showed that patients with pachychoroid neovasculopa-
thy were less genetically susceptible to AMD.
Genetic risk score for AMD susceptibility also differed significantly between the pachychoroid neovas-
culopathy and neovascular AMD groups (OR = 0.52 and 0.56, respectively; p = 3.8 × 10−3 and 1.5 × 10−2; 
per one score increase of genetic risk score weighted by Asian, and per one score increase of genetic risk 
score weighted by Caucasian, respectively) (Fig.  1). Again, the pachychoroid neovasculopathy patients 
showed less genetic susceptibility to AMD.
A total of 108 patients treated with ranibizumab were eligible for the survival analysis. Of them, 
28 individuals had pachychoroid neovasculopathy and 80 individuals had neovascular AMD (Table 4). 
The rate of dry macula after a loading dose did not differ significantly between the two groups (90.9% 
vs. 83.7%; p = 0.51). However, the Kaplan-Meier curves for the retreatment-free periods were signifi-
cantly different between the two groups (p = 9.5 × 10−3). Pachychoroid neovasculopathy had a longer 
retreatment-free period (Fig. 2).
Discussion
Pachychoroid neovasculopathy is a new clinical entity of CNV, which is characterized by its shared 
features with CSC or PPE17. However, pachychoroid neovasculopathy often masquerades as neovascular 
AMD, and standard diagnostic criteria have not yet been established. Since pachychoroid neovasculop-
athy may respond differently to photodynamic therapy or anti-VEGF therapy, discriminating it from 
neovascular AMD is of great importance. We hypothesized that pachychoroid neovasculopathy may 
commonly have been misdiagnosed as AMD, especially in Asians, and that this may partly explain 
the heterogeneity seen in neovascular AMD between Asians and Caucasians8. To estimate the prev-
alence of pachychoroid neovasculopathy, we investigated 200 CNV patients aged over 50, classifying 
them into pachychoroid neovasculopathy and neovascular AMD groups based on their phenotypes. In 
our cohort, pachychoroid neovasculopathy was seen with high frequency (one-fourth of neovascular 
AMD-diagnosed patients). In addition, our study revealed significantly different genetic backgrounds 
between the two groups.
As Table 1 shows, the overall clinical characteristics of the participants are similar to those previously 
reported in Japanese AMD patients. For example, pseudodrusen were observed in 9.0% of the patients, 
which is comparable to previous reports showing the prevalence of pseudodrusen in Japanese patients 
with AMD (10.8–16.8%)18,19. Our mean subfoveal choroidal thickness (227 ± 101 μ m in right eyes and 
229 ± 109 μ m in left eyes) was also similar to that found in previous reports (subfoveal choroidal thick-
ness; 204–245 μ m in neovascular AMD and 243–293 μ m in PCV)12,20. Considering the prevalence of cho-
roidal vascular hyperpermeability in cases of PCV has been reported to be 9.8–34.8%11–13, the prevalence 
of choroidal vascular hyperpermeability in the current study (16.5% in right eyes and 14.0% in left eyes) 
is comparable to that in previous reports.
Based on our diagnostic criteria, 39 patients (19.5%; confidence interval [CI], 14.0%–25.0%) were 
diagnosed with pachychoroid neovasculopathy. Patients with pachychoroid neovasculopathy were 
Pachychoroid neovasculopathy Neovascular AMD P-value
Number of patients 39 (19.5%) 161 (80.5%) –
Age (years) 68.7 ± 9.0 75.6 ± 8.3 5.1 × 10−5
Sex (male:female) 30:9 113:48 0.44
Refraction (diopter)* 0.57 ± 2.08 0.10 ± 2.17 0.22
RPE abnormality apart from the CNV legion 35 (89.7%) 49 (30.4%) 7.9 × 10−12
Chorodial Vessels dilatation (number of quadrants) 0.64 ± 0.73 0.43 ± 0.58 0.093
Choroidal vascular hyperpermeability 21 (53.8%) 22 (13.6%) 4.5 × 10−7
Subfoveal choroidal thickness (μ m) 310`± 53 208 ± 100 3.4 × 10−14
Polypoidal legion 22 (56.4%) 69 (42.9%) 0.11
Brinkman Index 482 ± 495 537 ± 625 0.56
Table 2. Characteristics of the pachychoroid neovasculopathy and neovascular AMD. AMD: age-related 
macular degeneration, RPE: retinal pigment epithelium. CNV: choroidal neovascularization. *Phakic eyes 
only; Average of both eyes are presented if both eyes are phakic.
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Data from n






control) AA AG GG
A-allele 
frequency P*
Normal (Japanese) Nagahama study 3,248 1312 1499 435 36.5% – – 546 1538 1162 40.5% − 
Pachychoroid neovasculopathy Current study 39 11 16 12 51.3%
0.029
1.83† 8 16 15 41.0%
0.013
Neovascular AMD Current study 161 24 64 71 64.8% 3.20† 17 48 96 25.5%
Neovascular AMD (Japanese) Arakawa et al. 1,536 – – – 57.4% – 2.41‡ – – – 27.1% –
Neovascular AMD (Caucasian) Sobrin et al. 1,775 – – – – – 3.67‡ – – – – –
Table 3.  Genotypic differences between the patients with pachychoroid neovasculopathy and 
neovascular AMD. *Adjusting for age and sex. †Compared to 3,248 normal Japanese. ‡Cited from the 
original paper. CSC: central serous chorioretinopathy, AMD: age-related macular degeneration, CNV: 
choroidal neovascularization.
Figure 1. Distribution of genetic risk score calculated from 11 SNPs of 11 AMD susceptibility genes. 
We constructed a multi-locus genetic risk score by summing up the number of risk alleles of each single 
nucleotide polymorphism (SNP), weighted by its reported effect size (log odds ratio, OR). We evaluated both 
genetic risk score using effect size in Caucasian (A) and that using effect size in Asian (B). The effect sizes 
applied in this analysis are summarized in Supplementary Table 2. Pachychoroid neovasculopathy patients 
had significantly lower genetic risk scores for AMD than did neovascular AMD patients.
Pachychoroid 
neovasculopathy Neovascular AMD
Number of patients 22 86
Age (years) 68.7 ± 8.5 74.1 ± 8.2
Sex (male:female) 5:17 27:59
Choroidal vascular hyperpermeability 15 (68.2%) 15 (17.4%)
Subfoveal choroidal thickness (μ m) 314 ± 58 227 ± 103
Polypoidal legion 11 (50.0%) 41 (47.7%)
Dry macula after loading dose 20 (90.9%) 72 (83.7%)
Table 4.  Summary of the patients who were eligible for the survival analysis. AMD: age-related macular 
degeneration.
www.nature.com/scientificreports/
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significantly younger than those with neovascular AMD, which was compatible with the original report17. 
In the current study, however, we evaluated only patients with age of more than 50 years because the 
main interest of this study was to contrast pachychoroid neovasculopathy to neovascular AMD. Thus, 
mean age of the patients with pachychoroid neovasculopathy could be rather younger. Since pachycho-
roid neovasculopathy, unlike neovascular AMD, is characterized by a lack of drusen, and the genetic 
backgrounds differed significantly between the two groups (Table 3, Fig. 1), the etiologies of these two 
conditions are likely to be different.
As shown in Table 3, the ARMS2 rs10490924 effect size for neovascular AMD (OR = 3.17) was higher 
than the previously reported effect size for Japanese neovascular AMD (OR = 2.41)21, while it was sim-
ilar to the same effect size for Caucasian neovascular AMD (OR = 3.67)22. It is possible that pachy-
choroid neovasculopathy was misdiagnosed and included among neovascular AMD cases in previous 
reports. This would have led to an underestimation of the effect of AMD susceptibility genes in Japanese 
patients. Furthermore, a similar underdiagnosis of pachychoroid neovasculopathy may have occurred in 
other Asian studies, considering the higher prevalence of CSC in Asia23,24. Indeed, in The AMD Gene 
Consortium paper, the effect sizes of ARMS2 rs10490924 and CFH rs10737680 for AMD were higher 
in Caucasian than in Asian patients, despite a lower prevalence of geographic atrophy, which is asso-
ciated with a lower risk allele frequency, in Asians (Supplementary Figures 2A and 2B of The AMD 
Gene Consortium paper)25. Interestingly, the CFH rs800292 A allele frequency in pachychoroid neo-
vasculopathy patients was comparable to that in normal Japanese subjects (41.0% vs. 40.5%, p = 0.92). 
Furthermore, these genetic findings were quite similar to our previous report that compared consecu-
tive CNVs with choroidal vascular hyperpermeability to those without14, CNVs with choroidal vascular 
hyperpermeability, which would correspond to pachychoroid neovasculopathy at least in part, had nor-
mal genotype distribution in terms of ARMS2 rs10490924 and CFH rs800292. Considering above, these 
CNVs should be distinguished from neovascular AMD.
Freund and colleagues hypothesized that pachychoroid neovasculopathy is associated with PCV16,17. 
Consistent with this, 56.4% of pachychoroid neovasculopathy cases are associated with polypoidal lesion. 
It follows that PCV figures may have been more augmented by misdiagnosed pachychoroid neovascu-
lopathy cases than the figures of other subtypes. This may explain why PCV have thicker choroid20,26, 
more frequent history of CSC11,27,28, and more favorable prognosis29, particularly in the Asian population. 
The results may also explain why the effect of ARMS2 rs10490924 is higher for AMD than for PCV in 
the Asian population30,31. All that being said, in our study 42.9% of eyes with neovascular AMD also 
had polypoidal lesion. Polypoidal legion is increasingly thought to be a manifestation of long-standing 
type 1 CNV in AMD as well as a variety of other diseases. In general, PCV has been considered as a 
subtype of neovascular AMD that accompanies polypoidal legion; thus, we suggest that pachychoroid 
Figure 2. Kaplan-Meier curve for retreatment-free period after loading dose of ranibizumab. We selected 
study participants who had received a loading dose of ranibizumab (3 × one-monthly injections, 0.5 mg), 
been treated as needed afterwards, and been followed up for more than 12 months. The duration from the 
third ranibizumab injection to the administration of additional treatment (event), or to the final visit by 
June 2014, or loss to follow up) was reported on a daily basis. A log-rank test revealed that the curves for 
pachychoroid neovasculopathy and neovascular AMD differed significantly from one another (p = 0.0095). 
Pachychoroid neovasculopathy showed longer retreatment-free period.
www.nature.com/scientificreports/
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neovasculopathy with polypoidal lesion should be distinguished from neovascular AMD with polypoidal 
lesion so as not to confuse the concepts of neovascular AMD and pachychoroid neovasculopathy.
To distinguish neovascular AMD and pachychoroid neovasculopathy is important not only because it 
is related to the etiology of CNV, but also because it can influence disease management. Our survival anal-
ysis showed that patients with pachychoroid neovasculopathy had a significantly longer retreatment-free 
period than those with neovascular AMD (p = 9.5 × 10−3) after a loading dose of anti-VEGF therapy. 
This indicates that pachychoroid neovasculopathy may be more self-limited or that VEGF secretion in 
pachychoroid neovasculopathy may be lower than in neovascular AMD. This hypothesis is compatible 
with the following observations: (1) CNV development takes a long time in pachychoroid neovascu-
lopathy; and (2) the VEGF concentration in the aqueous humor of PCV eyes, whose figures may have 
been more bloated by misdiagnosed pachychoroid neovasculopathy, was reported to be lower than that 
of neovascular AMD eyes32. On the other hand, the dry macula rate after loading dose was over 80% 
in both conditions, revealing no statistically significant difference between them (p = 0.51). That said, 
it must be stated that the loading dose may have been adequate to eliminate VEGF in both conditions 
except for 10%–20% of patients, who may have been non-responder.
While the current study has significant implications, it does have limitations. Firstly, the current crite-
ria for diagnosing pachychoroid neovasculopathy may not be ideal. Based on previous reports, we set our 
original diagnostic criteria – choroidal thickness, absence of drusen, choroidal vascular hyperpermeabil-
ity, and RPE abnormalities – because no standard diagnostic criteria for pachychoroid neovasculopathy 
have been established so far. The current criteria could be more sophisticated to distinguish pachycho-
roid neovasculopathy and neovascular AMD with higher sensitivity and specificity. For instance, cho-
roidal thickness varies with age and axial length33, so these parameters could be taken into account for 
diagnosis. As another example, we did not diagnose pachychoroid neovasculopathy when there was 
only one soft drusen in the fellow eye, in order to increase the specificity of the diagnosis. Ideally, the 
scoring method could have been employed to balance the sensitivity and specificity of the pachychoroid 
neovasculopathy diagnosis. Nonetheless, even though our criteria were based solely on phenotype, they 
successfully demarcated a cluster of CNV that was genetically distinct from neovascular AMD. Secondly, 
this study only included Japanese individuals. Considering the higher prevalence of CSC in Asians than 
in Caucasians, we speculate that pachychoroid neovasculopathy may have been misclassified as neovas-
cular AMD in Asians more often. Future studies including other ethnicities are indicated. Thirdly, the 
significant result in the survival analysis may need to be deducted from the study because it is based on 
retrospective data.
In conclusion, pachychoroid neovasculopathy was different from neovascular AMD not only phe-
notypically but also genetically. Pachychoroid neovasculopathy may represent up to one quarter of 
diagnosed neovascular AMD cases. Although pachychoroid neovasculopathy often masquerades as neo-
vascular AMD, their etiology is likely to be different because pachychoroid neovasculopathy shows lack 
of drusen and the genotype distribution of AMD susceptibility SNPs differed significantly between the 
two conditions. Pachychoroid neovasculopathy should be distinguished from neovascular AMD in future 
epidemiological and genetic studies. Lastly, further research is necessary to manage and prevent this 
disease.
Methods
The current study was approved by the Institutional Review Board at Kyoto University Graduate School 
of Medicine and adhered to the tenets of the Declaration of Helsinki. Written informed consent was 
obtained from each genotyped patient.
Subjects. We retrospectively reviewed the medical records of consecutive patients (1) who had visited 
the macular service of Kyoto University Hospital (Kyoto, Japan) between January 2010 and October 2012, 
agreed to participate in the genetic study (the participation rate ≥ 99%), and were genome-scanned, (2) 
who were diagnosed with either pachychoroid neovasculopathy or neovascular AMD (diagnostic criteria 
of these diseases are described in the following section), and (3) who were older than 50 years. Patients 
with the following conditions were excluded from the study: (1) CNV secondary to high myopia (spher-
ical equivalent, ≤ − 6.00 D or axial length of ≥ 26 mm), trauma, angioid streaks, uveitis, or any other 
neovascular maculopathy, (2) choroidal thickness not available due to thick hemorrhage, (3) history of 
ocular surgery other than cataract surgery. Smoking status was evaluated using the Brinkman Index 
([number of cigarettes per day] × [number of years smoking])34.
Multimodal Imaging Methods. All patients underwent a complete ophthalmologic examination, 
including measurement of best-corrected visual acuity, determination of intraocular pressure, indirect 
ophthalmoscopy, slit-lamp biomicroscopy with a non-contact lens, color fundus photography, infrared 
reflectance (IR), fundus autofluorescence (FAF), fluorescein angiography (FA), indocyanine green angi-
ography (IA), and spectral-domain optical coherence tomography (SD-OCT).
Color fundus photographs (field, 40°) were obtained digitally using a Topcon TRC NW6S 
non-mydriatic retinal camera (Topcon, Tokyo, Japan) after medical dilatation of the pupil (phenyle-
phrine 0.5% and tropicamide 0.5%). IR, FAF, FA, and IA images were acquired using a confocal SLO 
(Spectralis HRA+ OCT; Heidelberg Engineering, Heidelberg, Germany). IR images were obtained using 
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a light stimulus of 820 nm. FAF images were obtained using an excitation light of 488 nm and a barrier 
filter beginning at 500 nm. The field of view was set to 30° × 30° centered on the macula. SD-OCT was 
conducted using a Spectralis HRA+ OCT (Heidelberg Engineering). First, horizontal and vertical line 
scans through the fovea center were obtained at a 30° angle, followed by serial horizontal scans with 
an examination field size of 30° × 10°. Inverted OCT images, which enable us to measure choroidal 
thickness, were routinely obtained in all patients using an enhanced-depth imaging (EDI) technique35. 
At each location of interest on the retina, fifty SD-OCT images were acquired and averaged to reduce 
speckle noise.
Image Analysis and Phenotyping. Soft drusen were graded based on the fundus photographs 
according to the simplified severity scale for AMD from the Age-Related Eye Disease Study (AREDS)36. 
The occurrence of dot- or ribbon-type pseudodrusen was confirmed using color fundus photography, 
IR, FAF, IA (late phase), or when there was OCT evidence of definite drusenoid deposits above the RPE.
Subfoveal choroidal thickness and choroidal vascular hyperpermeability were evaluated as previously 
described14. Briefly, subfoveal choroidal thickness was defined as the vertical distance between Bruch’s 
membrane and the chorioscleral interface at the fovea, which was manually measured in the EDI-OCT 
images by a retinal specialist blinded to study parameters using the built-in caliber. Choroidal vascular 
hyperpermeability was determined by detecting multifocal hyperfluorescent areas with blurred margin 
that expanded during the late phase of IA (i.e., 10–15 minutes after dye injection) (Fig. 3A). Choroidal 
vascular hyperpermeability was confirmed only when independent judgments of two retinal specialists 
(M.M. and S.O.) were agreed. The number of quadrants with dilated choroidal vessels was also evaluated 
for each eye, based on wide-field IA images taken five to ten minutes after dye injection.
Figure 3. (A) Choroidal vascular hyperpermeability. Choroidal vascular hyperpermeability is evidenced 
by focal areas of hyperfluorescence, which appear during the middle phase of indocyanine green 
angiography (IA) and expand over time, eventually forming a ring shape (arrowheads). The center of 
the initially hyperfluorescent area becomes hypofluorescent during the late phase. (B) Retinal pigment 
epithelium abnormality. Retinal pigment epithelium (RPE) abnormality is seen as patchy areas of granular 
hypoautofluorescence with occasional discrete hyperautofluorescent specks scattered throughout the fundus 
autofluorescence (FAF) images16,17 (arrowheads). However, this was not considered indicative of RPE 
abnormality when this finding was adjacent to a choroidal neovascularization (CNV; arrows) lesion.
www.nature.com/scientificreports/
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RPE abnormality was determined by detecting patchy areas of granular hypoautofluorescence with 
occasional discrete hyperautofluorescent specks scattered throughout the FAF image, according to the 
original report of PPE16. RPE abnormality is often seen in CNV legion; therefore, only RPE abnormali-
ties occurring independent of CNV lesions were evaluated in this study (Fig. 3B). The presence of RPE 
abnormality was only confirmed when independent judgments of two retinal specialists (M.M. and S.O.) 
were agreed.
Definition of pachychoroid neovasculopathy. Although there is no established definition for 
pachychoroid neovasculopathy, the nature of this entity is type 1 CNV secondary to CSC or PPE, which 
often masquerades as AMD15,17. In this study, pachychoroid neovasculopathy was diagnosed if all of the 
following criteria were met: (1) CNV in either eye; (2) subfoveal choroidal thickness ≥200 μ m in both 
eyes; (3) no drusen or only non-extensive (total area, ≤ 125 μ m circle) hard drusen (≤ 63 μ m) in both 
eyes (AREDS category 1, no AMD); (4) CSC or PPE characteristics; namely, choroidal vascular hyper-
permeability (Fig. 3A), RPE abnormality independent of CNV lesion (Fig. 3B), the presence of dilated 
choroidal vessels or thickening below the type 1 CNV, or a history of CSC. Cases identified pachycho-
roid neovasculopathy are shown in Figs  4–6. Patients with CNV and other findings corresponding to 
AREDS categories 2, 3, and 4 (extensive hard drusen, soft drusen [intermediate, ≥ 63 and < 125 μ m; 
large, ≥ 125 μ m], pseudodrusen, focal hyperpigmentation, or geographic atrophy) were diagnosed with 
neovascular AMD.
Choroidal thickness is an important factor that characterizes PPE, though it is not included in the 
definition of CSC. Although the original report did note “focal, multifocal, or diffuse area of reddish 
orange background within the arcades with minimal to absent choroidal vascular markings (reduced 
fundus tessellation), indicative of a thickened choroid,” it was somewhat subjective16. For this reason, 
we employed a choroidal thickness threshold value instead. Because the original report presented a PPE 
case with a subfoveal choroidal thickness of 231 μ m, we set this threshold value at 200 μ m. In another 
study, the mean subfoveal choroidal thickness in CSC eyes was 414 μ m (95% range, 200 μ m–628 μ m), 
Figure 4. A case of pachychoroid neovasculopathy. A 50-year-old man visited the macular service 
at Kyoto University Hospital with a chief complaint of central scotoma in his right eye. (A,D) The 
color fundus photograph from the patient’s first visit shows serous retinal detachment without drusen. 
Fluorescein angiography (FA) shows late leakage (ink blot pattern; white arrow). Indocyanine green 
angiography (IA) image shows no choroidal neovascularization (CNV). Optical coherence tomography 
(OCT; vertical scan thorough the center of the fovea) shows serous retinal detachment and an almost flat 
retinal pigment epithelium (RPE) band. All these findings were compatible with a diagnosis of central 
serous chorioretinopathy (CSC). (E) Four months after the patient’s first visit: OCT shows persistent serous 
retinal detachment. (B,F) Ten months after the patient’s first visit: CNV is not apparent in either FA or IA. 
However, there are several protrusions in the OCT image. (G–I) 2.5 yr (G), 4.5 yr (H), and 6.5 yr (I) after 
the patient’s first visit. After spontaneous resolution of subretinal fluid, it again increased. The RPE band 
gradually elevated, suggesting the development of CNV (red arrows). (C,J) Seven years after the patient’s 
first visit, CNV is apparent in both FA/IA (white arrowheads) and OCT (red arrow) images. Choroid is thick 
all over the macula. Color fundus photography contains no drusen.
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while that of the contralateral eyes was 350 μ m (95% range, 123–577 μ m)37. This further supports the 
validity of our threshold value.
Genotyping. Genotyping was performed using the Illumina BeadChip; HumanOmni2.5, OmniExpress 
and/or HumanExome. Quality controls were conducted using PLINK ver1.07 (http://pngu.mgh.harvard.
edu/~purcell/plink/), and missing values were imputed using SHAPEIT2 (http://www.shapeit.fr/) and 
Figure 5. A case of pachychoroid neovasculopathy. A 68-year-old male was visually impaired in the right 
eye (best-corrected visual acuity = 30/20). (A) Color fundus photograph shows serous retinal detachment 
(arrowheads) without drusen. (B) FA suggests occult CNV. (C) Late-phase IA shows choroidal vascular 
hyperpermeability (arrowheads). (D) Enhanced depth imaging OCT (vertical scan thorough the center of 
the fovea) reveals type 1 CNV and subretinal fluid. Choroid is thick throughout the macula, and subfoveal 
choroidal thickness was measured as 353 μ m. He had GT genotype at ARMS2 A69S (rs10490924) and AG 
genotype at CFH I62V (rs800292).
Figure 6. Pachychoroid pigment epitheliopathy observed in the fellow eye of the patient in Fig. 5.  
(A) Color fundus photography shows no drusen. (B) FAF shows RPE abnormality associated with choroidal 
vascular dilation (arrow), but without hyperautofluorescent lesions, which would suggest the previous 
presence of subretinal fluid. (C) Enhanced depth imaging OCT (horizontal scan thorough the center of the 
fovea) shows thick choroid throughout the macula, and subfoveal choroidal thickness was 335 μ m. All these 
findings are compatible with a diagnosis of pachychoroid pigment epitheliopathy.
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IMPUTE2 (https://mathgen.stats.ox.ac.uk/impute/impute_v2.html) software. Details are described in 
Supplementary Notes.
As a reference group, we used 3,248 unrelated individuals from the general population, recruited from 
the Nagahama Prospective Genome Cohort for the Comprehensive Human Bioscience (The Nagahama 
Study)38–40. These patients were genotyped using HumanHap610 K quad arrays, HumanOmni2.5 M arrays, 
and/or HumanExome arrays (Illumina Inc., San Diego, CA). The two SNP genotypes were extracted from 
the cohort’s fixed dataset.
Gene/SNP selection and genetic risk score. From the 19 genes that were significantly associated 
with AMD in the report by The AMD Gene Consortium25, we used 11 genes whose associations with 
AMD were also verified in Asian individuals (Gene for AMD in Asian [GAMA] consortium)41. For CFH, 
C3, and CETP, we investigated single nucleotide polymorphisms (SNPs) that have commonly been 
reported in Asians14,38,42–45, rather than those reported by The AMD Gene Consortium. Altogether, the fol-
lowing SNPs were investigated in this study: ARMS2 (rs10490924), CFH (rs800292), C2/CFB (rs429608), 
C3 (rs2241394), APOE (rs4420638), CETP (rs3764261), VEGFA (rs943080), TNFRSF10A (rs13278062), 
CFI (rs4698775), TGFBR1 (rs334353), and ADAMTS9 (rs6795735).
We constructed a multi-locus genetic risk score by summing up the number of risk alleles of each 
SNP, weighted by their reported effect sizes (log odds ratio, OR). Because of the possibility that the effect 
size in Asians did not reflect the true AMD susceptibility because of errors in the sample introduced 
by wrongly diagnosed cases of pachychoroid neovasculopathy, we evaluated genetic risk score using the 
effect sizes in both Caucasian and Asian populations. The effect sizes applied in this analysis are sum-
marized in Supplementary Table 2.
Survival analysis. To evaluate the clinical importance of pachychoroid neovasculopathy, we selected 
study participants who had received a loading dose of ranibizumab (3 monthly injections, 0.5 mg), 
received treatment as needed afterwards, and been followed up for more than 12 months. After exclud-
ing the patients who had had previous ocular treatment (other than cataract surgery), and those with a 
visual acuity less than 20/200, we retrospectively reviewed medical charts. The durations from their third 
ranibizumab injection to event (the administration of additional treatment) or censoring (final visit by 
June 2014, or loss to follow up) was reported on a daily basis.
Statistical analysis. Every 2 × 2 table was evaluated using Fisher’s exact test. Continuous variables 
were compared using the unpaired t-test. Genotype distribution was compared using the chi-square 
test for trends. Survival analysis on the retreatment-free period was conducted using the Kaplan-Meier 
method. Differences between curves were evaluated using the log-rank test. A p-value < 0.05 was con-
sidered statistically significant. These statistical analyses were conducted using R software ver.3.02 (http://
www.r-project.org/). For the survival analysis, the CRAN package “survival” was employed.
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